Finance

Lists
Why is KPTI down 20.64%?
Dive Deeper
KPTI:NASDAQ
Karyopharm Therapeutics Inc
$1.29
-20.64%
(-0.33) 1D
Sep 29, 1:59:40 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KPTI...
Open
$1.62
High
$1.62
Low
$1.26
Mkt. cap
29.16M
Avg. vol.
1.27M
Volume
903.18K
52-wk high
$10.99
52-wk low
$1.24
EPS
-$12.84
Beta
0.95
Shares outstanding
22.68M
No. of employees
228
Open
$1.62
High
$1.62
Low
$1.26
Mkt. cap
29.16M
Avg. vol.
1.27M
Volume
903.18K
52-wk high
$10.99
52-wk low
$1.24
EPS
-$12.84
Beta
0.95
Shares outstanding
22.68M
No. of employees
228
News stories
From web sources and news partners
About Karyopharm Therapeutics Inc
CEO-
Employees228
Founded2008
HeadquartersNewton, Massachusetts, United States
SectorBiotechnology
Websitekaryopharm.com
Analyst ratings
Based on 6 analysts giving stock ratings to KPTI in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KPTI in the last 3 months.
Highest
Current $1.29
$11.00 (+755.57%)
Average
$6.54 (+408.67%)
Lowest
$3.00 (+133.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
$3.68
+186.2%
09/01/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$8.00
+522.2%
08/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
$11.00
+755.6%
07/31/2026
Colleen M. Kusy
Robert W. Baird
Hold
Downgraded
-
-
07/31/2026
Edward Tenthoff
Piper Sandler
Buy
Maintained
$7.00
+444.5%
07/31/2026
Robert Burns
H.C. Wainwright
Hold
Downgraded
$3.00
+133.3%
07/31/2026
Unknown Analyst
Leerink Partners
Hold
Reiterated
$7.00
+444.5%
05/15/2026
Michael King
Rodman & Renshaw
Buy
Initiated
$28.00
+2,077.8%
03/09/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$2.32 / -$1.39
-66.91%miss
Revenue / Est. (USD)
33.43M / 32.19M
+3.85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
44.04M
34.08M
35.07M
33.43M
Cost of goods sold
32.66M
29.15M
35.14M
30.04M
Cost of revenue
32.66M
29.15M
35.14M
30.04M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.61M
22.77M
26.68M
25.92M
Operating expense
26.61M
22.77M
26.68M
25.92M
Total operating expenses
59.26M
51.92M
61.83M
55.96M
Operating income
-15.22M
-17.84M
-26.76M
-22.53M
Other non operating income
-7.42M
-10.04M
16.41M
-32.08M
EBT including unusual items
-33.09M
-102.26M
-22.39M
-67.02M
EBT excluding unusual items
-33.09M
-39.90M
-22.39M
-67.02M
Income tax expense
34.00K
-67.00K
1.00K
-
Effective tax rate
-0.10%
0.07%
-
-
Other operating expenses
-
-
-
-
Net income
-33.13M
-102.20M
-22.39M
-67.02M
Net profit margin
-75.21%
-299.89%
-63.86%
-200.48%
Earnings per share
-3.82
-2.23
-1.24
-2.32
Interest and investment income
553.00K
607.00K
511.00K
722.00K
Interest expense
-11.01M
-12.62M
-12.55M
-13.14M
Net interest expenses
-10.46M
-12.01M
-12.04M
-12.42M
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.10M
-17.82M
-26.75M
-22.52M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps